Melanie Mooney, MD
Family Medicine · Rincon, GANPI 1861462970
Payments from drug & device makers
Across 188 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$618
- Novo Nordisk$546
- Pfizer$385
- AstraZeneca$273
- Amgen$214
- Boehringer Ingelheim$212
- plus $943 from 26 others
What the payments were for
- Food & beverage$3,16199%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 37 | $618 |
| Novo Nordisk | 36 | $546 |
| Pfizer | 20 | $385 |
| AstraZeneca | 17 | $273 |
| Amgen | 14 | $214 |
| Boehringer Ingelheim | 13 | $212 |
| Bayer | 5 | $94 |
| Exact Sciences | 5 | $94 |
| Novartis | 4 | $83 |
| AbbVie(2 entities) | 4 | $69 |
| Sumitomo Pharma America, Inc. | 2 | $59 |
| Abbott | 3 | $51 |
| Dexcom, Inc. | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 3 | $49 |
| GSK | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Sequel Med Tech, LLC | 1 | $28 |
| Amarin Pharma, Inc. | 2 | $28 |
| Boston Scientific | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $22 |
| Lifescan, Inc. | 1 | $21 |
| Abiomed | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| PBG Puerto Rico LLC | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$3,191 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 83 | $91,203 |
| EliquisApixaban | 67 | $63,789 |
| OzempicSemaglutide | 40 | $41,030 |
| MounjaroTirzepatide | 22 | $37,040 |
| TrulicityDulaglutide | 21 | $27,016 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $24,845 |
| LinzessLinaclotide | 20 | $22,218 |
| XareltoRivaroxaban | 11 | $18,347 |
| GemtesaVibegron | 24 | $17,258 |
| RybelsusSemaglutide | 14 | $14,274 |
| Repatha SureclickEvolocumab | 19 | $12,376 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $8,873 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $4,442 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,293 |
| Atorvastatin Calcium | 443 | $3,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $212 | $91,20383 claims |
| Lilly USA, LLCMounjaro, Trulicity | $618 | $64,05743 claims |
| PfizerEliquis | $385 | $63,78967 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $546 | $58,22570 claims |
| GSKTrelegy Ellipta | $46 | $24,84521 claims |
| AbbVieLinzess, Synthroid | $69 | $24,77161 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $59 | $17,25824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Rincon
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.